PrEP use high but wanes after three months among young African women

In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among young African women and adolescent girls, 95% initiated PrEP, and most used PrEP for the first three months. However, PrEP use fell in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored strategies may be needed to engage young African women in consistent PrEP use.
Go to Source